RareCyte Secures Funding for Groundbreaking Research
RareCyte, Inc., a pioneering leader in precision biology and innovative liquid biopsy technology, has achieved a significant milestone by obtaining a $500K grant from the Gates Foundation. This funding is aimed at advancing critical research into fetal growth restriction (FGR), a condition that is a leading cause of premature births and neonatal complications globally.
Understanding Fetal Growth Restriction
FGR represents a major health challenge that affects countless pregnancies. It can lead to long-term developmental issues for children and raises health risks for mothers. Despite its widespread occurrence, the exact causes of FGR are often poorly understood, making it crucial to develop effective diagnostic tools to identify the condition early.
The Power of TrophoSeq Technology
At the heart of RareCyte's approach is the innovative TrophoSeq™ assay. This unique technology facilitates a non-invasive 'liquid biopsy' of placental tissue by isolating and sequencing circulating trophoblasts (circTBs) from maternal blood samples. Eric Kaldjian, MD, RareCyte's Senior Vice President of Clinical Research and the research's principal investigator, emphasizes that these rare placental cells provide invaluable insights into placental function. This allows researchers to investigate molecular alterations associated with both healthy and problematic pregnancies without posing any risk to the mother or child.
Collaboration with Renowned Research Institutions
In an exciting collaborative effort, RareCyte will partner with skilled researchers, including Prof. Mushi Matjila and Dr. Nadia Ikumi from the University of Cape Town. Together, they will embark on a comprehensive two-phase study involving pregnant women at Groote Schuur Hospital. This research will focus on generating detailed cellular and transcriptomic profiles of circTBs from 30 participants experiencing early-onset FGR compared to those with typical pregnancies.
Advancements in Placental Research
Prof. Matjila expresses enthusiasm about this project, stating, "By employing this innovative technology, we can enhance our understanding of placental biology, particularly during the early stages of pregnancy. This approach not only respects the integrity of ongoing pregnancies but also helps nurture local talent and research capabilities. The project aims to identify differences in gene expression and molecular pathways linked to placental dysfunction, which could lead to better diagnostic tools and therapeutic targets in the future."
Key Objectives of the Study
Several key highlights define this pilot study:
- Non-invasive sampling: The research utilizes maternal blood for placental cell retrieval, removing the risks linked to traditional biopsy methods.
- Global health impact: The study targets early-onset FGR—a condition associated with significant perinatal morbidity and mortality.
- Data-driven insights: It involves comprehensive transcriptomic analyses to uncover the underlying molecular causes of FGR.
- Collaborative approach: Findings will be analyzed in partnership with UCT and shared throughout the scientific community.
Future Implications for Maternal and Neonatal Health
Joe Victor, CEO of RareCyte, shares the company’s vision: "By pushing the boundaries of research on fetal growth restriction, we aim to provide healthcare professionals and researchers with the tools necessary to predict, diagnose, and ultimately prevent adverse pregnancy outcomes." The expected completion date for this pilot study is set for the first half of 2026. The outcomes will influence future research and global endeavors aimed at enhancing maternal and neonatal health.
About RareCyte, Inc.
RareCyte focuses on providing Precision Biology products and services dedicated to discovery, translational research, and clinical diagnostics. With the Orion™ spatial biology platform, they enable multiplexed tissue analysis, and their extensive liquid biopsy offerings facilitate characterization of circulating tumor cells (CTCs) and other rare cells for molecular analysis and development of companion diagnostics. It's important to note that these products are intended for research use only and are not applicable for diagnostic procedures.
About the University of Cape Town
The University of Cape Town (UCT) stands out as a leading research institution on the African continent, committed to excellence in education, research, and community engagement. UCT fosters an inclusive environment welcoming diverse scholars and students, focusing on creating local relevance in its global initiatives. The university plays a crucial role in advancing scholarship in Africa while producing graduates equipped to lead and innovate for a better future.
Frequently Asked Questions
What is RareCyte, Inc. known for?
RareCyte, Inc. specializes in precision biology and liquid biopsy technologies for clinical diagnostics and research applications.
What is Fetal Growth Restriction?
Fetal Growth Restriction (FGR) is a medical condition where a fetus does not grow to its expected weight, leading to increased risks for complications in pregnancy outcomes.
How does the TrophoSeq™ assay work?
TrophoSeq™ assay allows non-invasive testing by retrieving and analyzing placental cells circulating in maternal blood, providing insights into placental health.
What will the research study focus on?
The study will focus on identifying differences in gene expression and pathways related to placental health by comparing samples from pregnancies affected by FGR and healthy pregnancies.
When are the results expected?
The pilot study is anticipated to conclude in the first half of 2026, with results influencing future maternal and neonatal health research.
